Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.

RU58841 cured seborrheic dermatitis, oily scalp, dandruff, and scalp pain, improving hair health when combined with Minoxidil. Another user noted diet impacts their seborrheic dermatitis and that finasteride hasn't changed their condition.

A user's hair growth progress over 5 months using Fin 2.5mg gel and Redensyl serum, with the user noticing baby hairs and an improvement in thickness. Another user asked what redensyl serum was and the response was appreciation for noticing the hair loss early on.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

Minoxidil-dependent hairs fall out if minoxidil is stopped. New treatments like GT20029, FOL055, or TDM105795 might help sustain these hairs.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

The user showed a 4-month hair loss treatment progress using topical finasteride with minoxidil, Redensyl, Procapil, Capixyl, ketoconazole shampoo, and occasional microneedling. They took consistent progress photos under the same conditions.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A sugar gel has been found to aid hair regrowth, similar to minoxidil, and may improve blood supply to hair follicles. Some users report success with homemade versions, though side effects like dizziness have been noted.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

A 24-year-old male has been using 0.1% finasteride and 5% minoxidil daily for four months, added dermarolling and topical dutasteride, and sees hair regrowth, improving from a Norwood scale 4a to 3a. He wants to optimize his hair loss treatment routine.

The conversation is about a user's four-month progress using finasteride, minoxidil, and weekly dermastamping for hair loss. People occasionally notice improvements in the user's hair.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

A 29-year-old male with androgenic alopecia was treated with oral Dutasteride, oral Minoxidil, and injectable Dutasteride, showing progress in 9 months. Some users believe Dutasteride mesotherapy is unnecessary and question its effectiveness compared to topical applications.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

The user switched from finasteride to DIY dutasteride mesotherapy and topical minoxidil due to side effects. They report improved well-being and no hair loss worsening after stopping finasteride.

A 23-year-old male shares his 4-month hair regrowth progress using oral minoxidil, oral finasteride, collagen, biotin, keto shampoo, and dermarolling. He notices fuller hair but minimal visible change, and considers adding topical minoxidil despite concerns about consistency.

A user shared 3 months of progress using daily Dutasteride 0.5mg and Minoxidil 5mg, with Dutasteride mesotherapy every 4 months. They prefer not to use additional treatments for now.

A user reported significant hair regrowth after 4 months using finasteride and minoxidil, with no major side effects. They are considering oral minoxidil and use microneedling and ketoconazole shampoo.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

A user's successful 4-month hair growth progress using Hims spray with 6% Minoxidil, 0.3% Finasteride, and a .25mm dermaroller twice a week. The user applies the spray once a day and has not experienced any side effects.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

User "mo_movic" shared 4-month progress using finasteride, minoxidil, ketoconazole, and dermaroller for hair loss. Others congratulated and discussed their own experiences, with "mo_movic" reducing finasteride dose and using ketoconazole twice a week.

Oral minoxidil was ineffective for OP, causing hair loss and unwanted body hair, while topical minoxidil showed significant regrowth. OP is switching to topical minoxidil with glycerin due to scalp issues with propylene glycol.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.